简介:天津天使力联合制药公司生产的复方丹参滴丸,作为我国中药复方制剂的开路先锋,已被美国FDA接受直接进入Ⅱ-Ⅲ期新药临床试验,实现了国药走向世界的历史性突破。为实施国家中药现代化科技产业行动计划,实现中国医药产业与国际接轨,推动我国民族医药产业健康发展,国家科委新药研究与开发协调领导小组会同国家科委等7部委,经过认真讨论和筛选,确定天津天使力联合制药公司生产的复方丹参滴丸为首选产品,直接申请在美国进入新药临床研究(IND)。国家科委生命科学技术发展中心(美国)与天津天使力联合制药公司一起,在国家科委新药研究与开发海外专家委员会、美国哈佛大学公共卫生学院、医学院、美国国立卫生研究院哈佛大学替代医学中心和美国有关制药公司从事新药研究与开发的专家的协同努力下,经过8个多月的艰苦工作,已于1997年12月9日,正式通过美国FDA对复方丹参滴丸进行新药临床研究的预审,同意该产品在临床设计方案完成后,直接进入美国新药审批程序中的临床Ⅱ-Ⅲ期合并试验。这是我国首次也是全世界范围内,唯一一个通过美国FDA作为临床治疗心血管疾病的传统中药。
简介:AbstractBackground:Taxanes are an essential class of antineoplastic agents used to treat various cancers and are a fundamental cause of hypersensitivity reactions. In addition, other adverse events, such as bone marrow toxicity and peripheral neuropathy, can lead to chemotherapy discontinuation. This study aimed to evaluate the safety of taxanes in the real world.Methods:Taxane-associated adverse events were identified by the Medical Dictionary for Regulatory Activities Preferred Terms and analyzed and compared by mining the US Food and Drug Administration Adverse Event Reporting System pharmacovigilance database from January 2004 to December 2019. Reported adverse events, such as hypersensitivity reaction, bone marrow toxicity, and peripheral neuropathy, were analyzed with the following signal detection algorithms: reporting odds ratio (ROR), proportional reporting ratio (PRR), multi-item gamma Poisson shrinker (MGPS), Bayesian confidence propagation neural network (BCPNN), and logistic regression methods. Adverse outcome events and death outcome rates were compared between different taxane groups using Pearson’s χ2 test, whereas significance was determined at P < 0.05 with a 95% confidence interval (CI).Results:A total of 966 reports of hypersensitivity reactions, 1109 reports of bone marrow toxicity, and 1374 reports of peripheral neuropathy were analyzed. Compared with paclitaxel and docetaxel, bone marrow toxicity following the use of nab-paclitaxel had the highest ROR of 6.45 (95% two-sided CI, 6.05-6.88), PRR of 5.66, (χ2 = 4342.98), information component of 2.50 (95% one-sided CI = 2.34), and empirical Bayes geometric mean of 5.64 (95% one-sided CI = 5.34). Peripheral neuropathy following the use of nab-paclitaxel showed a higher ROR of 12.78 (95% two-sided CI, 11.55-14.14), PRR of 12.16 (χ2 = 4060.88), information component of 3.59 (95% one-sided CI = 3.25), and empirical Bayes geometric mean of 12.07 (95% one-sided CI = 11.09).Conclusions:The results showed that bone marrow toxicity and peripheral neuropathy were the major adverse events induced by taxanes. Nab-paclitaxel exhibited the highest potential for taxane-associated adverse events. Further research in the future is warranted to explain taxane-associated adverse effects in real-world circumstances.